Meeting Tue, 04/18/2023 - 12:00 Drug Prior Authorization Committee Meeting Information

Date
Media
Edit Implementation Schedule April 2023
New Drugs Edits April 2023
PDL Announcements April 2023
PDL Recommendations April 2023
Conduent Reports April 2023
MO Board of Pharmacy Continuing Education April 2023
MO Pharmacy Advisory Board Slides April 2023
Agenda
Agenda April 2023
Minutes
Minutes April 2023
Criteria
DUR Criteria
Clinical Edit Proposals – Existing Criteria
Media
Acne and Rosacea Select Topical Agents April 2023
Fabry Disease April 2023
Givlaari April 2023
Imcivree April 2023
Isturisa April 2023
Megestrol Acetate April 2023
Nulibry April 2023
Oxervate April 2023
Oxlumo April 2023
Scenesse April 2023
Sickle Cell Disease April 2023
Spravato April 2023
Systemic Antifungals April 2023
Tavneos April 2023
Voxzogo April 2023
Zokinvy April 2023
Zulresso April 2023
DUR Criteria
Clinical Edit Proposals – New or Revised Criteria
Media
Hemgenix April 2023
Tzield April 2023
DUR Criteria
Preferred Drug List Edit Proposals – Existing Criteria
Media
Actinic Keratosis Agents Topical April 2023
Androgenic Agents April 2023
Antibiotics Inhaled April 2023
Anticholinergics LABA Combinations April 2023
Anticholinergics Short Acting and Combos Inhaled April 2023
Antifungals Topical April 2023
Antihistamines Decongestant Combos 2G April 2023
Antihistamines Intranasal April 2023
Antiparasitics Topical April 2023
Antivirals Herpes Oral April 2023
Benzoyl Peroxide Antibiotic Combinations April 2023
Beta Adrenergic Agents Nebulized April 2023
Beta Adrenergic Agents Short Acting April 2023
Corticosteroids Ophthalmic Soft April 2023
Corticosteroids Topical April 2023
Cough and Cold Preparations April 2023
Fluoroquinolones Ophthalmic April 2023
Fluoroquinolones Otic April 2023
Hepatitis C Agents April 2023
Leukotriene Receptor Modifiers April 2023
Mast Cell Stabilizers Ophthalmic April 2023
NSAIDS Ophthalmic April 2023
Pancreatic Enzyme Agents April 2023
Retinoids Topical April 2023
DUR Criteria
Preferred Drug List Edit Proposals – New or Revised Criteria
Media
Anticholinergics LABAs ICS Combos PDE4 Inhibitors April 2023
Anticholinergics Long Acting Inhaled April 2023
Antifungals Oral April 2023
Antihistamines Ophthalmic April 2023
Antivirals Topical April 2023
Beta Adrenergic Agents Long Acting April 2023
Corticosteroids and Rhinitis Agents Intranasal April 2023
Epinephrine Agents Self Injectable April 2023
Glaucoma Agents April 2023
Inflammatory Bowel Disease Agents Oral April 2023
Inflammatory Bowel Disease Agents Rectal April 2023
Page
Drug Prior Authorization Committee Meeting Information